DPP4 and type 2 diabetes mellitus: Despite the discovery of effective medications for T2DM, such as Glucagon-like Peptide-1 (GLP1) agonists, Dipeptidyl peptidase 4 (DPP4) inhibitors, and sulfonylureas, most of these therapies rely on β cells to secrete insulin.